A detailed history of Glenview Trust CO transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Glenview Trust CO holds 100,139 shares of BMY stock, worth $3.97 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
100,139
Previous 99,556 0.59%
Holding current value
$3.97 Million
Previous $5.11 Million 6.3%
% of portfolio
0.12%
Previous 0.13%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$47.98 - $54.4 $27,972 - $31,715
583 Added 0.59%
100,139 $5.43 Million
Q4 2023

Feb 12, 2024

SELL
$48.48 - $57.85 $501,186 - $598,053
-10,338 Reduced 9.41%
99,556 $5.11 Million
Q3 2023

Nov 13, 2023

BUY
$57.89 - $64.73 $25,876 - $28,934
447 Added 0.41%
109,894 $6.38 Million
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $68,934 - $76,540
1,082 Added 1.0%
109,447 $7 Million
Q1 2023

May 09, 2023

SELL
$65.71 - $74.53 $32,197 - $36,519
-490 Reduced 0.45%
108,365 $7.51 Million
Q4 2022

Feb 08, 2023

BUY
$68.48 - $81.09 $152,025 - $180,019
2,220 Added 2.08%
108,855 $7.83 Million
Q3 2022

Nov 04, 2022

SELL
$0.13 - $76.84 $30 - $17,980
-234 Reduced 0.22%
106,635 $7.58 Million
Q2 2022

Aug 10, 2022

BUY
$72.62 - $79.98 $80,608 - $88,777
1,110 Added 1.05%
106,869 $8.23 Million
Q1 2022

May 11, 2022

SELL
$61.48 - $73.72 $42,851 - $51,382
-697 Reduced 0.65%
105,759 $7.72 Million
Q4 2021

Feb 10, 2022

SELL
$53.63 - $62.52 $218,756 - $255,019
-4,079 Reduced 3.69%
106,456 $6.64 Million
Q3 2021

Nov 12, 2021

SELL
$59.17 - $69.31 $2,425 - $2,841
-41 Reduced 0.04%
110,535 $6.54 Million
Q2 2021

Aug 11, 2021

SELL
$61.91 - $67.42 $172,357 - $187,697
-2,784 Reduced 2.46%
110,576 $7.39 Million
Q1 2021

May 12, 2021

SELL
$59.34 - $66.74 $147,044 - $165,381
-2,478 Reduced 2.14%
113,360 $7.16 Million
Q4 2020

Feb 02, 2021

SELL
$57.74 - $65.43 $90,825 - $102,921
-1,573 Reduced 1.34%
115,838 $7.19 Million
Q3 2020

Nov 12, 2020

SELL
$57.43 - $63.64 $107,566 - $119,197
-1,873 Reduced 1.57%
117,411 $7.08 Million
Q2 2020

Aug 12, 2020

SELL
$54.82 - $64.09 $99,827 - $116,707
-1,821 Reduced 1.5%
119,284 $7.01 Million
Q1 2020

Apr 28, 2020

SELL
$46.4 - $67.43 $187,688 - $272,754
-4,045 Reduced 3.23%
121,105 $6.75 Million
Q4 2019

Feb 06, 2020

BUY
$49.21 - $64.19 $1.46 Million - $1.9 Million
29,573 Added 30.94%
125,150 $8.03 Million
Q3 2019

Nov 14, 2019

SELL
$42.77 - $50.71 $35,328 - $41,886
-826 Reduced 0.86%
95,577 $4.85 Million
Q2 2019

Aug 08, 2019

SELL
$44.62 - $49.34 $87,142 - $96,361
-1,953 Reduced 1.99%
96,403 $0
Q1 2019

May 14, 2019

SELL
$45.12 - $53.8 $65,965 - $78,655
-1,462 Reduced 1.46%
98,356 $4.69 Million
Q4 2018

Feb 14, 2019

BUY
$48.76 - $63.23 $19,699 - $25,544
404 Added 0.41%
99,818 $5.19 Million
Q3 2018

Nov 14, 2018

BUY
$55.19 - $62.25 $10,817 - $12,201
196 Added 0.2%
99,414 $6.17 Million
Q2 2018

Aug 10, 2018

SELL
$50.53 - $62.98 $117,532 - $146,491
-2,326 Reduced 2.29%
99,218 $5.49 Million
Q1 2018

May 14, 2018

SELL
$59.92 - $68.98 $121,038 - $139,339
-2,020 Reduced 1.95%
101,544 $0
Q4 2017

Feb 06, 2018

SELL
$59.94 - $65.35 $14,385 - $15,683
-240 Reduced 0.23%
103,564 $6.35 Million
Q3 2017

Nov 07, 2017

BUY
$55.23 - $63.74 $5.73 Million - $6.62 Million
103,804
103,804 $6.62 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $84.3B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Glenview Trust CO Portfolio

Follow Glenview Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Glenview Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Glenview Trust CO with notifications on news.